Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | EXCEED-ET: ropeginterferon alfa-2b in adults with essential thrombocythemia

Lucia Masarova • 8 Jun 2023
ASCO 2023
Essential Thrombocythemia Myeloproliferative Neoplasms Rare Diseases Ropeginterferon alfa-2b
EXCEED-ET

Lucia Masarova, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the design of the Phase I/II EXCEED-ET trial (NCT05482971), which aims to evaluate the efficacy of ropeginterferon alfa-2b in adults with essential thrombocythemia (ET), discussing the primary and secondary endpoints of the study.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Lucia Masarova

1:19
What's on the horizon for the treatment of MPNs?
Lucia Masarova • 9 Dec 2023
2:13
Splicing mutations in post-ET/post-PV myelofibrosis
Lucia Masarova • 9 Dec 2023
3:17
Estimating transfusion-related medical costs & time burden in patients with MF in SIMPLIFY-1
Lucia Masarova • 9 Dec 2023
3:18
Cladribine-based chemotherapy for patients with secondary AML arising after MPNs
Lucia Masarova • 9 Dec 2023

Related Videos

2:45
Continuity of care for patients with hematological predispositions to AML
Anupama Rao • 29 Apr 2024
1:23
The current treatment landscape for patients with T-cell prolymphocytic leukemia
Dima El-Sharkawi • 28 Apr 2024
1:13
The current BSH guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
Mary Frances McMullin • 28 Apr 2024
1:46
Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
The content of VJHemOnc is intended for healthcare professionals